Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142


Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease.

Alonso-Padilla J, de Oya NJ, Blázquez AB, Escribano-Romero E, Escribano JM, Saiz JC.

Vaccine. 2011 Feb 17;29(9):1830-5. doi: 10.1016/j.vaccine.2010.12.081. Epub 2011 Jan 4.


A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.

Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF.

Virol J. 2010 Jul 6;7:146. doi: 10.1186/1743-422X-7-146.


Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus.

Martina BE, Koraka P, van den Doel P, van Amerongen G, Rimmelzwaan GF, Osterhaus AD.

Vaccine. 2008 Jan 10;26(2):153-7. Epub 2007 Nov 20.


A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.

Schneeweiss A, Chabierski S, Salomo M, Delaroque N, Al-Robaiy S, Grunwald T, Bürki K, Liebert UG, Ulbert S.

Vaccine. 2011 Aug 26;29(37):6352-7. doi: 10.1016/j.vaccine.2011.04.116. Epub 2011 May 17.


Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE).

Escribano-Romero E, Gamino V, Merino-Ramos T, Blázquez AB, Martín-Acebes MA, de Oya NJ, Gutiérrez-Guzmán AV, Escribano JM, Höfle U, Saiz JC.

Vaccine. 2013 Sep 23;31(41):4523-7. doi: 10.1016/j.vaccine.2013.07.071. Epub 2013 Aug 6.


A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.

McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi VN, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell TJ.

J Infect Dis. 2007 Jun 1;195(11):1607-17. Epub 2007 Apr 17.


A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.

Bonafé N, Rininger JA, Chubet RG, Foellmer HG, Fader S, Anderson JF, Bushmich SL, Anthony K, Ledizet M, Fikrig E, Koski RA, Kaplan P.

Vaccine. 2009 Jan 7;27(2):213-22. doi: 10.1016/j.vaccine.2008.10.046. Epub 2008 Nov 7.


Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.

Gershoni-Yahalom O, Landes S, Kleiman-Shoval S, Ben-Nathan D, Kam M, Lachmi BE, Khinich Y, Simanov M, Samina I, Eitan A, Cohen IR, Rager-Zisman B, Porgador A.

Immunology. 2010 Aug;130(4):527-35. doi: 10.1111/j.1365-2567.2010.03251.x. Epub 2010 Mar 16.


Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.

Desprès P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F.

J Infect Dis. 2005 Jan 15;191(2):207-14. Epub 2004 Dec 10.


Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.

Throsby M, Ter Meulen J, Geuijen C, Goudsmit J, de Kruif J.

Expert Rev Vaccines. 2007 Apr;6(2):183-91. Review.


Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.

Schepp-Berglind J, Luo M, Wang D, Wicker JA, Raja NU, Hoel BD, Holman DH, Barrett AD, Dong JY.

Clin Vaccine Immunol. 2007 Sep;14(9):1117-26. Epub 2007 Jul 18.


Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

Dunn MD, Rossi SL, Carter DM, Vogt MR, Mehlhop E, Diamond MS, Ross TM.

Virol J. 2010 May 12;7:95. doi: 10.1186/1743-422X-7-95.


Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.

Samina I, Havenga M, Koudstaal W, Khinich Y, Koldijk M, Malkinson M, Simanov M, Perl S, Gijsbers L, Weverling GJ, Uytdehaag F, Goudsmit J.

Vaccine. 2007 Nov 28;25(49):8338-45. Epub 2007 Oct 15.


A recombinant envelope protein vaccine against West Nile virus.

Ledizet M, Kar K, Foellmer HG, Wang T, Bushmich SL, Anderson JF, Fikrig E, Koski RA.

Vaccine. 2005 Jun 10;23(30):3915-24. Epub 2005 Apr 6.


Protection provided by a recombinant ALVAC(®)-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain.

Minke JM, Siger L, Cupillard L, Powers B, Bakonyi T, Boyum S, Nowotny N, Bowen R.

Vaccine. 2011 Jun 20;29(28):4608-12. doi: 10.1016/j.vaccine.2011.04.058. Epub 2011 May 5.


Antibodies targeting linear determinants of the envelope protein protect mice against West Nile virus.

Ledizet M, Kar K, Foellmer HG, Bonafé N, Anthony KG, Gould LH, Bushmich SL, Fikrig E, Koski RA.

J Infect Dis. 2007 Dec 15;196(12):1741-8. doi: 10.1086/523654.


Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01.

Iyer AV, Pahar B, Boudreaux MJ, Wakamatsu N, Roy AF, Chouljenko VN, Baghian A, Apetrei C, Marx PA, Kousoulas KG.

Vaccine. 2009 Feb 5;27(6):893-903. doi: 10.1016/j.vaccine.2008.11.087. Epub 2008 Dec 12.


Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.

De Filette M, Soehle S, Ulbert S, Richner J, Diamond MS, Sinigaglia A, Barzon L, Roels S, Lisziewicz J, Lorincz O, Sanders NN.

PLoS One. 2014 Feb 4;9(2):e87837. doi: 10.1371/journal.pone.0087837. eCollection 2014.

Items per page

Supplemental Content

Write to the Help Desk